Get started
Author

Borislav Borissov

Observed names: B Borissov, B. Borissov, Borisov Borislav
Observed institution: Medical University of Sofia
ORCID: 0000-0003-1711-0284
Observed ORCID: 0000-0003-1711-0284
OpenAlex ID: A5065419807
Funding breakthrough therapies: A systematic review and recommendation
2017 · E. Hanna, M. Toumi, et al. · Health Policy · 56
Regenerative medicine regulatory policies: A systematic review and international comparison
2020 · Tingting Qiu, Eve Hanna, et al. · Health Policy · 53
PDF
Patient-reported outcome claims in European and United States orphan drug approvals
2018 · Szymon Jarosławski, Pascal Auquier, et al. · Journal of Market Access & Health Policy · 19
Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
2017 · Borislav Borissov, Michael Urbich, et al. · Journal of Market Access & Health Policy · 10
PDF
Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
2018 · Szymon Jarosławski, Pascal Auquier, et al. · Journal of Market Access & Health Policy · 9
PDF
Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers
2021 · Tingting Qiu, Shuyao Liang, et al. · Frontiers in Public Health · 8
PDF
Gene therapy randomised clinical trials in Europe – a review paper of methodology and design
2020 · Krassimira Ilieva, Borislav Borissov, et al. · Journal of Market Access & Health Policy · 5
Cost-Effectiveness Analysis of Innovative Therapies for Patients with Non-Alcoholic Fatty Liver Disease
2024 · Michal Pochopien, Jakub Wladyslaw Dziedzic, et al. · Journal of Market Access & Health Policy · 3
PDF
Why “American Patients First” is likely to raise drug prices outside of the United States
2019 · Monique Dabbous, Cyprien Milea, et al. · Journal of Market Access & Health Policy · 2
PDF
Current controversies of using cost per QALY for cost- effectiveness analysis-Isn’t two decades enough?
2019 · Borislav Borissov · Biomedical Research and Clinical Practice · 2
PDF
Cost-effectiveness of the ABCStroke pathway in ischaemic stroke care: a UK pilot analysis
2026 · Borislav Borissov, Dimitrios Sagris, et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 1
The dual economic impact of COVID-19 vaccine hesitancy - Bulgaria’s conundrum case
2025 · Svetlin Georgiev, Borislav Borissov, et al. · Pharmacia · 1
PDF
EE283 Cost-Effectiveness Analysis of Cell-Based Therapy for Patients with Non-Alcoholic Fatty Liver Disease
2022 · S Aballea, P Karwala, et al. · Value in Health · 1
PDF
Joint collaborations and future perspectives for gene therapies.
2020 · Monique Dabbous, Borislav Borissov, et al. · Cell and Gene Therapy Insights · 1
Completeness as an Emerging Doctrine: Article 9 and the Admissibility Gateway in the European Union’s Joint Clinical Assessments
2026 · Mondher Toumi, Malgorzata Wozniak, et al. · Preprints.org
Epistemological Tensions in the EU HTA Joint Clinical Assessment: The Illusion of Judgment-Free Evaluation
2026 · Mondher Toumi, Bruno Falissard, et al. · Journal of Market Access & Health Policy
PDF
CO158 Analysis of Clinical Endpoints in Clinical Trials for NAFL and NASH: A Comprehensive Review
2023 · M. Pochopien, J. Dziedzic, et al. · Value in Health
EE320 Impact of NASH Disease Model Adjustment to New Literature Findings: Assessing Cost-Effectiveness of Actual and Theoretical Treatments
2023 · M. Pochopien, J. Dziedzic, et al. · Value in Health
PDF
EE179 Key Drivers of the Economically Justifiable Price of the COVID-19 Vaccine in England
2022 · S Aballea, P Karwala, et al. · Value in Health
PDF
Pnd108 Quality of Life of Patients After Ischaemic Stroke Treated in a Provincial Hospital in Poland
2019 · S. Jarosławski, B. Jarosławska, et al. · Value in Health
PDF
Pmd55 the Learning Curve as a Barrier in the Conduct of Randomized Controlled Trials With Medical Devices - a Literature Review
2019 · B. Borissov · Value in Health
PDF
Pcn385 Pay-for-performance in Oncology: a Successful Story From Bulgaria
2019 · B. Borissov · Value in Health
Pcn232 Divergent Hta Decisions in Europe for Oncology Drugs Granted Breakthrough Designation
2019 · B. Borissov · Value in Health
PDF
A Review of Patient-Reported Outcome Data for Palliative Cancer Drugs Approved In the European Union
2018 · Borislav Borissov · Palliative Medicine & Care Open Access
PDF
Analysis of Medicinal Products’ Expenditure Reimbursed by the National Health Insurance Fund in Bulgaria for Outpatient Care
2016 · Petya Trendafilova, Tatyana Benisheva, et al. · Open Journal of Social Sciences
PDF
Works count: 25
Citation count: 171
H-index: 6
I10-index: 4
Year
Topic
Type